Phase 2 N=15 The Effect of an Antibiotic on the Production of Uremic Toxins by the Gut Microbiome
End Stage Renal Disease
Primary: Change in Plasma Concentration Measure of Indoxyl Sulphate (IS) — -25.31; 9.71 µM/ml
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=40 Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
Adult Solid Neoplasm · Childhood Solid Neoplasm · Recurrent Childhood Central Nervous System Neoplasm
Primary: The Number of Participants With Dose Limiting Toxicities to Determine the Maximum Tolerated Dose of Temozolomide and Talazoparib Combination Therapy — 0; 0; 1; 2…
Phase 2 N=8 Ustekinumab (STELARA) for the Treatment of Active Sight-Threatening Uveitis (STAR Study)
Uveitis
Primary: Number of Participants Experiencing a Treatment Response by Week 16 — 4; 2 Participants
Phase 2 N=69 Effects of Metformin During Nicotine Withdrawal
Smoking · HIV-1-infection
Primary: Mood Following 24h of Smoking Abstinence — 36.5; 33.8; 37.9; 14.3 score on a scale
Phase 2 N=72 Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
Postmenopausal Women · Locally Advanced Metastatic Breast Cancer · Metastatic Breast Cancer
Primary: Percentage of Participants With Overall Response Rate (ORR) — 37.2 Percentage of Participants
Phase 2 N=160 Long Term Extension Study Evaluating Safety, Tolerability and Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
Alzheimer Disease
Primary: Percentage of Participants With Treatment-emergent AEs or Serious Adverse Events (SAEs) — 100.0; 100.0; 93.8; 92.9 percentage of participants
Phase 2 N=37 Confocal Endoscopic Microscopy for Detection of Early Stage Gastric Cancer in Subjects With Hereditary Diffuse Gastric Cancer Syndrome
Gastric Cancer · Gastric Neoplasms
Primary: Percentage of Participants With Detectable Confocal Endoscopic Microscopy (CEM) w/Greater Sensitivity for Detection of Signet Ring Cells (SRC)Foci in Cadherin-1 (CDH1)…
Phase 2 N=456 Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure With Reduced Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-REDUCED)
Heart Failure
Primary: Change From Baseline in Log-Transformed N-Terminal Pro-Brain Natriuretic Peptide (NTproBNP) to Week 12 — -0.28; -0.265; -0.32; -0.353 log-transformed picograms per…
Phase 2 N=40 Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation to Treat Radiation Retinopathy.
Radiation Retinopathy
Primary: Mean Change in Early Treatment Diabetic Retinopathy Study (ETDRS) Visual Acuity at 104 Weeks From Day 0. — -1.9; -3.9; 1.3 letters
Phase 2 N=47 Cholera Anti-Secretory Treatment Trial
Cholera
Primary: Diarrheal Stool Output Rate — 25.42; 32.57 mL/hour — p=0.2254
Phase 2 N=18 Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Adenocarcinoma of the Prostate · Hormone-resistant Prostate Cancer · Recurrent Prostate Cancer
Primary: Maximum Tolerated Dose (MTD) of Pasireotide in Combination With Docetaxel and Prednisone by the Occurrence of Adverse Events and the Associated Grade Per NCI Common…
Phase 2 N=43 Reduced Carbohydrate Versus Fat in Obese Subjects
Obesity
Primary: Change in Respiratory Quotient (RQ) — -0.0552; 0.00453 ratio
Phase 2 N=6 A Study of Siliphos in Adults With Non-alcoholic Steatohepatitis (NASH)
Fatty Liver
Primary: Number of Study Participants With Adverse Events — 0; 0 Participants
Phase 2 N=45 Open-Label Phase IIb Efficacy Trial of Cancer Macrobeads Compared to Best Supportive Care in Colorectal Cancer Patients
Colorectal Cancers
Primary: Overall Survival — 9.25 months
Phase 2 N=70 HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed GBM
Brain and Central Nervous System Tumors
Primary: Number of Participants With Treatment-Related Adverse Events of Any Grade — 34 Participants